The University of Virginia Comprehensive Cancer Center) seeks men ages 18 and over with prostate cancer for a research study. The study will evaluate the investigational trial product called VTP-850, which is an experimental drug not yet approved by the FDA, for the treatment of prostate cancer. The main purpose of this trial is to find out how safe the trial drug VTP-850 is in people with prostate cancer who have had initial treatment but their prostate-specific antigen (PSA) levels have started to rise again.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have essential thrombocythemia and need to start with therapy to reduce their blood count or whose current therapy is not sufficiently controlling their disease. The purpose of the study is to learn if the study drug, P1101 (Ropeginterferon alfa-2b-njft) can normalize blood counts. The safety of P1101 will also be studied. P1101 is an FDA approved dug, but it has not been FDA approved to treat essential thrombocythemia.

The University of Virginia is participating a clinical research study for adults ages 18 and over, who have advanced cancer. The main purpose of this study is to evaluate whether NX-1607, an oral study drug, is safe and tolerated, and to identify the highest dose that can safely be given. Another main purpose of this study is to evaluate whether NX-1607 has an effect on the cancers being studied.

The University of Virginia is participating a clinical research study for adults ages 18 and over, who have mesothelioma. The purpose of the study is to compare the effects of chemotherapy combined with durvalumab, a type of immunotherapy, or to a treatment chosen by your study doctor, which is either chemotherapy or immunotherapy combination (ipilimumab and nivolumab) in mesothelioma.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have recurrent breast cancer. The main reason for you to take part in this study is to find out if researchers can lower the chance of your breast cancer coming back again by adding a drug called ribociclib to the usual hormone therapy drugs.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Metastatic Colorectal Cancer with a KRAS or NRAS Mutation to participate in a research study. The study will evaluate if the addition of the investigational agent onvansertib to standard anti-cancer treatment of FOLFIRI and bevacizumab will improve results in treating your type of cancer. Onvansertib is considered an investigational drug for use in this study because it has not been approved by the FDA.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Polycythemia (PV). Ropeginterferon alfa-2b-njft is an investigational drug that has been approved by the US FDA to treat PV, and the goal of Ropeginterferon alfa-2b-njft is to normalize blood counts, reduce the risk of blood clotting and bleeding, and to slow disease progression. The approved dosing for Ropeginterferon alfa-2b-njft requires a starting dose of 100 mcg and will increase 50mcg every 2 weeks.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed and/or refractory acute myeloid leukemia. The purpose of the study is to look at the safety and efficacy of the study drug, voruciclib, alone, or in combination with venetoclax, how your body tolerates the drug or drug combination, how effective the drug(s) may be, and how the drug is taken up by your body after multiple doses over the course of the study.

The University of Virginia Center for Diabetes Technology seeks adults between the ages of 18-80 who have diagnosed with type 2 diabetes for at least one year to participate in a research study. The purpose of this study is to gather data that will be used to develop a future web-based application that will help doctors take better care of people living with type 2 diabetes. This study will ask for the collection of data that is generated as a part of your normal health care. A study Dexcom G6 Continuous Glucose Monitor (CGM) will be provided to you to use during the study.

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have a KRAS pG12C mutation in lung or colorectal cancer. The purpose of this study to evaluate an investigational drug, sotorasib in combination with chemotherapies or another investigational drug. The safety and effects of the investigational treatment will be assessed for this study.